This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Denlinger CS , Matkowskyj KA , Mulcahy MF
Gastric and esophageal cancers: Guidelines updates
JNCCN Journal of the National Comprehensive Cancer Network. 2021 May;19(5.5) :639-643
PMID: WOS:000677828700015 URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85108549832&doi=10.6004%2fjnccn.2021.5006&partnerID=40&md5=848420b7d4e2e0b9fa5c6f9ac0567f43
AbstractFor the treatment of gastric and esophageal cancers, several pivotal trials-especially those evaluating immune checkpoint inhibitors (ICIs)-have altered the treatment landscape and led to changes in the NCCN Guidelines. In addition to pembrolizumab and nivolumab, new treatment options include trastuzumab-deruxtecan (T-DXd), ramucirumab, and trifluridine/tipiracil. These agents convey varying degrees of benefit depending on treatment line, PD-L1 expression, HER2 expression, and tumor histology. Recently, ICIs have been incorporated into the first-line treatment of HER2-negative advanced esophageal, gastroesophageal junction (GEJ), and gastric cancers, in addition to second-line treatment of advanced esophageal and GEJ cancer of squamous histology. T-DXd is another new second-line option for HER2-positive esophageal, GEJ, and gastric adenocarcinomas. ICIs are now moving into the adjuvant setting as well, and a new recommendation is nivolumab use after preoperative chemoradiation and surgery in patients who have residual disease identified at the time of their R0 resections.
NotesExport Date: 1 July 2021